

A Retrospective Study Assessing the Appropriateness of the Initial Antibiotic Therapy for Select Intra-Abdominal Infections

Background

- The need for antimicrobial stewardship is becoming more prevalent as resistance rates and adverse effects increase throughout the United States
- Intra-abdominal infections such as appendicitis, diverticulitis, and cholangitis occur in >300,000 patients annually
- They are the second leading cause of mortality in the ICU

Objectives

- Assess the initial antimicrobial therapy used in patients with cholangitis, diverticulitis, or appendicitis.
- Assess the total duration of treatment of these patients.


Methods

- This study was a single-center retrospective patient case review
- We selected 95 patients with appendicitis, diverticulitis, or cholangitis from January 17th 2022 to November 30th 2022
- Pediatric patients were excluded in the analyses
- Initial antimicrobial regimen appropriateness was determined by referencing the latest IDSA recommendations and risk factors
- The risk factors used to assess included: immunocompromised patients, age >70, physiological instability, and delay in care >24h
- The durations of treatment (secondary outcome) were compared to results of the STOP-IT trial and the DURAPOP Randomized Controlled Trial

Nick Vidmar, PharmD Candidate, Edward Weiler, PharmD, Aakash Patel, PharmD, BCIDP

Res

- Overall, 49.47% of patients received approx
- Only one of the risk factors used for this stu antimicrobials such as piperacillin/tazobac
- A total of 49 patients had zero risk factors, factors, and four had three risk factors. With
- 92.59%, 68.75%, and 100% patients received The average days of therapy was 9.81 days
- Overall, 8/95 (8.42%) of patients received \bullet received therapy for ≤ 7 days, and 36/95 (3'



Limitations

Limitations of this study included being a single center study, a small patient population, and failure to determine timing of sufficient source control due to unclear patient surgery notes.

ults opriate the	rapy	• Ap
ctam or imits, 27 had or ithin these ived approp	heeded to indicate broader ipenem/cilastatin. The risk factor, 16 had two risk patient subgroups, 14.29%, or iate therapy, respectively or \leq 4 days, 25/95 (26.32%)	 sel Ina dri dri the wi Th reg eva tre ass
py Appropriate	by Number of Risk Factors	 Pa ap Dut
	25	
	25	rec
	11	for
	5 4	• O 1
2		of
N	Y N Y Y	OI
1	2 3	rec
Total Num	ber of Risk Factors	• Po
able 2: Initial Ant	imicrobial Therapy	nh
	83/95 (87.4%)	PII
am	69/95 (72.6%) 7/95 (7.4%)	ste
	8/95 (8.4%)	for
	12/95 (12.6%)	
	8/95 (8.4%)	
	2/95 (2.1%) 1/95 (1.1%)	
	1/95 (1.1%)	

*Imipenem/cilastatin and cefazolin. **One ciprofloxacin and one aztreonam had no anaerobic coverage.

Email: Nvidmar@siue.edu

Conclusion

opropriate initial antimicrobial therapies were
lected about half of the time
appropriate use was observed to be primarily
iven by providing overly-broad spectrum
erapy like piperacillin/tazobactam to patients
th zero risk factors
nis could be due to physicians having a preferred
gimen for intra-abdominal infections, the lack of
aluation of risk factors listed within the
eatment guidelines, or incomplete risk factor
sessments in available order sets
tients with risk factors present received
propriate therapy more often
aration of treatment was slightly above the most
cent recommendations for duration of therapy
r intra-abdominal infections
utliers in duration could have been due to a lack
effective source control or the risk of
occurrence for certain patients
ossible solutions could include educating
ysicians on the importance of antimicrobial
ewardship and implementation of new strategies
r assessing patient risk factors.

Author Contact